Litcius/Paper detail

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Bryan J. Schneider, Christina Lacchetti, Kathryn Bollin

2022JCO Oncology Practice19 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAdverse effectInternal medicineImmune systemImmunotherapyOncologyPembrolizumabNivolumabClinical trialProgrammed cell death 1DiscontinuationIpilimumabMEDLINEIntensive care medicineImmunologyDiseaseImmune checkpointAntibody therapyCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchNeuroendocrine Tumor Research Advances